BioIntelliSense

What BioIntelliSense does

BioIntelliSense, Inc. is a privately held medical device and clinical intelligence company founded in 2019 and headquartered in Golden, Colorado, with an additional office in Redwood City, California. The company has built a medical-grade Data-as-a-Service (DaaS) continuous patient monitoring platform anchored on its FDA-cleared BioButton family of wearable devices — rechargeable multi-patient, rechargeable single-patient, and single-use variants — that continuously capture heart rate, respiratory rate, skin temperature, and activity at up to 1,440 measurements per patient per day. BioButton data is relayed via BioHub Wi-Fi or cellular gateways (or the BioMobile patient app) to BioCloud for algorithmic analysis, with results surfaced through BioDashboard, an FDA-cleared clinical intelligence system supporting exception-based monitoring at less than one alert per patient per day and predictive deterioration notifications averaging 14.8 hours in advance.

The company serves hospitals and health systems, including a landmark deployment across 2,653 non-ICU beds at all eight Houston Methodist hospitals, post-acute and skilled nursing facilities, rural and critical access hospitals, and hospital-at-home programs spanning transitional care and chronic disease management (CHF, COPD, oncology, transplantation, diabetes, hypertension). BioIntelliSense sells exclusively through enterprise channels — direct sales to provider organizations and strategic channel partnerships, notably with Hicuity Health (managed virtual monitoring services across 35 states) and Oracle Health's Device Validation Program for EHR-integrated device connectivity. Revenue is generated through annual subscription contracts priced per monitored bed or deployment scale, with hardware included in the subscription; at-home use additionally qualifies for Remote Patient Monitoring (RPM) reimbursement pathways.

The company has raised approximately $140 million cumulatively across disclosed rounds from 2019 through 2025, with Fresenius Medical Care and Chimera Investment among named investors. It received FDA clearance in October 2024 for the BioButton Multi-Patient wearable and BioDashboard system, acquired AlertWatch in October 2022 for clinical decision support, and has reported monitoring 400,000+ patients cumulatively as of October 2025.

Name

BioIntelliSense

Legal name

BioIntelliSense, Inc.

Website

https://biointellisense.com

Company type

Private

Founded year

2019

Operating status

Operating

Headcount range

51–100 employees

Short description

BioIntelliSense is a medical device and clinical intelligence company that sells an FDA-cleared continuous patient monitoring platform — BioButton wearable, BioHub gateways, BioCloud analytics, and BioDashboard — to hospitals, health systems, and post-acute care providers for in-facility and at-home vital sign monitoring.

Ownership category

akta.pro rank

Product category

Continuous Patient Monitoring

NAICS

Electromedical and Electrotherapeutic Apparatus Manufacturing (334510), Navigational, Measuring, Electromedical, and Control Instruments Manufacturing (3345)

SIC

Surgical & Medical Instruments & Apparatus (3841), Measuring & Controlling Devices, Nec (3829)

akta.pro primary industry

Clinical-Grade Vital Signs Monitoring (ECG, SpO2, BP, Temp, Respiration) (HLACAPAI)

akta.pro secondary industries

Connected Medical Devices & Wearables (Sensors, Patches, Implantables) (HLACAPAB), Vital Signs Monitoring (Multi-parameter, Spot-Check & Continuous) (HLAHACAA)

Keywords

• Continuous patient monitoring
• Wearable health monitoring
• Remote patient monitoring
• Clinical intelligence platform
• Vital sign monitoring

Headquarters

HQ city

Golden

HQ country

United States

HQ region

North America

Offices2 records

Markets served

GTM type

B2B

Offering type

Software

Cost components

Technology or R&D, Personnel, Supply Chain, Marketing or Sales, Operations, Infrastructure

Revenue model

1. BioButton Device and Hardware Sales: BioIntelliSense sells its BioButton wearable devices and associated hardware (BioHub gateways, charging stations) as part of a Data-as-a-Service (DaaS) platform. Hardware is provided under subscription arrangements. The BioButton Multi-Patient is rechargeable and reusable, while the BioButton Rechargeable is a single-patient device used in facility-to-home transitions.
2. Subscription-Based SaaS / Data-as-a-Service (DaaS) Platform: BioIntelliSense operates on a subscription/subscription services model. The Service Level Agreement references 'Monthly Service Fee' defined as 1/12 of annual subscription fees for the current contract year. The platform includes BioCloud data analytics, BioDashboard clinical intelligence, and support services bundled under subscription fees. The company offers an SLA with 99.9% uptime guarantee for its cloud-based services (BioCloud and BioDashboard).
3. RPM Reimbursement (Remote Patient Monitoring): The at-home monitoring solution supports Remote Patient Monitoring (RPM) reimbursement under CPT codes. Patients are discharged from hospital wearing a BioButton and receive a kit enabling continuous monitoring at home, offloaded via BioMobile app or BioHub cellular gateway. The RPM reimbursable workflow enables healthcare providers to bill for continuous monitoring services, creating a pathway for cost coverage for at-home patient monitoring.
4. Managed/Virtual Care Monitoring Services: Through the Hicuity Health partnership, BioIntelliSense's platform is integrated into fully managed, end-to-end continuous patient monitoring services offered to hospitals and health systems. This creates a managed services revenue pathway where the combined solution addresses infrastructure and staffing challenges for virtual care programs.

Pricing tiers

Go-to-market motion2 records

Distribution channels3 records

Marketing channels5 records

Core offering

BioIntelliSense sells a medical-grade Data-as-a-Service (DaaS) continuous patient monitoring platform for hospitals, health systems, and home-based care. The BioButton wearable captures up to 1,440 multi-parameter vital sign measurements per patient per day and transmits them via BioHub gateways to BioCloud, where algorithmic and AI-driven analytics feed the BioDashboard clinical intelligence system that enables proactive deterioration detection and scalable exception-based monitoring across inpatient and at-home settings.

Product overview

BioIntelliSense offers a medical-grade Data-as-a-Service (DaaS) platform for continuous patient monitoring spanning in-hospital to home care. The product portfolio centers on the BioButton family of multiparameter wearable devices (including rechargeable multi-patient, single-use, and charging station variants), BioHub gateways (Wi-Fi and cellular), BioMobile application, and the BioCloud/BioDashboard analytics and clinical intelligence system. The platform captures continuous vital signs including heart rate, respiratory rate, skin temperature, and activity levels, transmitting data via Bluetooth to gateways and then to the cloud for AI-driven analysis. The BioDashboard enables scalable exception management allowing single clinicians to monitor hundreds of patients. The company also offers the Rural Health Transformation Program for program design support.

Differentiator

Problem solved

Functional benefit

Brands

• BioButton: Multi-parameter continuous monitoring wearable device for vital sign and biometric measurements.
• BioHub
• BioMobile
• BioCloud
• BioDashboard

Products and services

• BioButton Multi-Patient FDA-cleared rechargeable and reusable multi-parameter wearable applied to patients at admission for continuous in-facility vital sign monitoring. Captures heart rate at rest, respiratory rate at rest, skin temperature, and activity levels with minute-level granularity for up to 14 days, transmitting data via Bluetooth to BioHub gateways. Sold as part of the Data-as-a-Service platform to hospitals and health systems.
• BioButton Rechargeable Rechargeable BioButton device designed for single-patient facility-to-home monitoring transitions. Patients are discharged wearing the device and receive a kit with charger and extra adhesives for at-home monitoring that supports Remote Patient Monitoring reimbursement under CPT codes. Sold as part of the Data-as-a-Service platform.
• BioButton Single Use Single-use disposable BioButton variant for applications where reuse is not appropriate, providing the same continuous vital sign monitoring capabilities in a disposable form factor. Sold as part of the Data-as-a-Service platform.
• BioButton Charging Station Dedicated charging station accessory for the BioButton Multi-Patient device that enables in-facility recharging and disinfection between patient uses, supporting cost-effective system-wide scaling. Sold as part of the BioButton platform.
• BioHub Wi-Fi Gateway Wi-Fi enabled gateway device placed in patient rooms that receives Bluetooth data from the BioButton wearable and transmits it to the BioCloud for analysis. Used in in-facility continuous monitoring deployments.
• BioHub Cellular Gateway Cellular-enabled gateway device that transmits BioButton data to the cloud without requiring home Wi-Fi connectivity, enabling at-home patient monitoring and supporting facility-to-home transitions.
• BioMobile Application Patient-facing mobile application that serves as a gateway for data transfer from the BioButton device to providers, enabling at-home continuous monitoring without dedicated hardware. Supports Remote Patient Monitoring reimbursable workflows.
• BioCloud Cloud-based data analytics platform that receives, stores, and analyzes continuous vital sign data from BioButton devices via BioHub gateways. Employs algorithmic and rules-based notifications to alert healthcare providers to adverse vital sign trends and early indications of patient deterioration, on average 14.8 hours before events. Delivered with a 99.9% uptime SLA under the Data-as-a-Service subscription.
• BioDashboard FDA-cleared clinical intelligence system and exception management software that displays analyzed vital sign data and personalized trend notifications. Enables scalable centralized monitoring across hospital and home settings with low alert rates of fewer than one notification per patient per day, supporting hospital command centers and remote clinical oversight.
• Rural Health Transformation Program Program design support service for healthcare organizations responding to Rural Health Transformation (RHT) Letters of Intent and Requests for Proposal, providing scalable continuous monitoring program designs, anticipated impact data, and direct engagement for rural facilities. Targeted at rural hospitals, critical access hospitals, and rural health clinics.

Quantifiable outcome

• 14.8 hours average early notification before patient deterioration events
• +10 more outcomes

Named customers3 records

Segments4 records

Ideal customer profiles4 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability4 records

Feature6 records

Partnerships

Four partnerships are on record, tiered core and minor.

• Oracle HealthcoreTechnology or Integration · 25 February 2026BioIntelliSense is a named device partner in Oracle Health's Device Validation Program, a standardized approach for validating medical device connectivity, functionality, and workflow alignment across healthcare organizations. The program uses an EHR-agnostic architecture allowing validated medical devices to connect to any electronic health record system, reducing IT burden while supporting secure, accurate data transmission and compliance with interoperability standards.
• Hicuity HealthcoreStrategic or Co-development Partner · 17 February 2025BioIntelliSense and Hicuity Health formed a strategic partnership to offer fully managed, end-to-end continuous patient monitoring to hospitals and health systems. The partnership integrates BioIntelliSense's FDA-cleared BioButton wearable and BioDashboard clinical intelligence system with Hicuity Health's 24/7 virtual patient monitoring services. This addresses critical infrastructure and staffing challenges, enabling health systems to deploy scalable monitoring solutions for in-hospital care, hospital-at-home programs, post-hospital discharge, and chronic remote care management. Hicuity Health delivers over 11 million hours annually of patient monitoring across a nationwide client base in 35 states.
• Houston MethodistcoreStrategic or Co-development Partner · 24 April 2024Houston Methodist completed a system-wide expansion of the BioButton continuous patient monitoring solution across all 2,653 non-ICU beds at the system's eight hospitals. The deployment, part of Houston Methodist's 'Vitals Redesign' initiative, was implemented in an accelerated six-month cycle. The monitoring program enables centralized command center monitoring by Houston Methodist's multidisciplinary team, with AI-driven analytics detecting clinically meaningful changes in vital sign trends. Houston Methodist also plans to expand use to emergency department triage and hospital-to-home programs.
• UC Davis HealthminorStrategic or Co-development Partner · 1 November 2023UC Davis Health launched a continuous monitoring program with BioIntelliSense for bone marrow transplant recipients. The program enables remote continuous monitoring of high-risk bone marrow transplant patients post-transplant, addressing the need for early detection of complications in a vulnerable patient population.

Scale indicators10 records

Recent moves6 records

Expansion highlights6 records

Broad incumbents

• Philips Healthcare: Philips offers continuous patient monitoring solutions, wearable biosensors, and connected care platforms for hospitals, directly overlapping with BioIntelliSense on continuous ward monitoring and remote patient monitoring, while also selling broader capital equipment and enterprise informatics.
• Masimo: Masimo is an established patient monitoring and pulse oximetry leader that has expanded into continuous wearable monitoring (Radius PPG) and hospital automation platforms, overlapping with BioIntelliSense on continuous vital sign capture and clinical-grade wearable sensors while serving a much broader portfolio.
• Medtronic: Medtronic offers remote patient monitoring solutions including LINQ insertable cardiac monitors and broader connected care platforms, competing with BioIntelliSense in continuous remote monitoring while operating a far larger diversified medtech business.
• Boston Scientific (Preventice / BodyGuardian): Boston Scientific acquired Preventice Solutions, which offers BodyGuardian remote cardiac monitoring, overlapping with BioIntelliSense on wearable continuous monitoring and remote patient monitoring while operating a much broader interventional and cardiac device portfolio.
• GE HealthCare: GE HealthCare provides continuous wearable patient monitoring (Portrait Mobile) and enterprise hospital monitoring solutions, competing with BioIntelliSense on continuous vital sign capture while offering a much wider portfolio of imaging, monitoring, and care delivery products.
• Welch Allyn / Baxter Spot Vital Signs: Welch Allyn (now part of Baxter's patient monitoring portfolio) provides spot-check vital signs devices used in routine nursing workflows, competing with BioIntelliSense's value proposition of replacing intermittent spot-checks with continuous monitoring, though lacking a continuous wearable offering.

Direct peers

• VitalConnect: VitalConnect offers the VitalPatch wearable biosensor for continuous multi-parameter vital sign monitoring in hospital and home settings, directly competing with BioIntelliSense's BioButton on form factor, FDA-cleared continuous monitoring, and remote patient monitoring workflows.
• EarlySense (Hillrom / Baxter): EarlySense (acquired by Hillrom, now part of Baxter) provides contact-free continuous patient monitoring sensors for early deterioration detection in hospital beds, directly competing with BioIntelliSense's continuous monitoring value proposition for non-ICU inpatient units.

Emerging players

• iRhythm Technologies: iRhythm's Zio wearable cardiac monitor provides ambulatory continuous ECG monitoring, partially overlapping with BioIntelliSense's continuous wearable monitoring franchise but focused specifically on cardiac arrhythmia detection rather than multi-parameter vital signs.

Others

• Hicuity Health: Hicuity Health is BioIntelliSense's strategic channel partner providing 24/7 virtual patient monitoring services to health systems across 35 states, representing both an immediate distribution channel and a comparable telehealth/monitoring services business model rather than a direct hardware competitor.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/biointellisense

Compliance1 record

Revenue estimate

Valuation estimate

Number of profiles

Profiles4 records

Funding overview

Funding rounds5 records

Investors7 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about BioIntelliSense